AstraZeneca profit jumps 23% on cancer drugs despite Farxiga generics

AstraZeneca (AZN) said on Friday October 30 that its quarterly profit rose 23%. Cheaper generic copies cut into sales of its diabetes drug Farxiga in the US. The company also launched a $1.5 billion yearly savings plan and will put the money into new drugs. Its shares rose in early trading.

Touched assets

Sources

AstraZeneca Q3 Profit Jumps 23% on Cancer Drugs, Launches $1.5B Savings Plan; Shares Rise 4.5% Oct 30 as Generics Hit Farxiga
The whole story · updated
E
Euronews
·
AstraZeneca profit jumps 23% on cancer drugs as it unveils major savings plan

The whole feed is waiting

Sign in to read every post and follow wallets.
Sign in